Dato-DXd联合度伐利尤单抗一线治疗晚期三阴性乳腺癌:BEGONIA研究7/8臂结果
BEGONIA平台研究7/8臂评估Dato-DXd联合度伐利尤单抗一线治疗不可切除局部晚期或转移性三阴性乳腺癌。7臂不限PD-L1表达(62例),确认客观缓解率79.0%;8臂PD-L1高表达(33例),确认客观缓解率81.8%。联合方案安全性可控,无新安全信号,无论PD-L1状态均显示持久抗肿瘤活性。
要点
- 7臂确认客观缓解率79.0%(95%CI 66.8-88.3),中位缓解持续时间17.6个月。
- 7臂中位无进展生存期14.0个月,中位总生存期未达到。
- 8臂确认客观缓解率81.8%(95%CI 64.5-93.0),中位随访10.7个月。
核心结论
- 一线Dato-DXd联合度伐利尤单抗在局部晚期不可切除或转移性三阴性乳腺癌中显示显著且持久的抗肿瘤活性。
- 疗效不受肿瘤PD-L1表达状态影响。
研究设计与样本
- BEGONIA(NCT03742102)为Ib/II期、Simon两阶段、开放标签平台研究。
- 7臂入组不限PD-L1表达患者62例,8臂入组PD-L1高表达患者33例。
- 患者接受Dato-DXd 6 mg/kg静脉联合度伐利尤单抗1120 mg静脉,每3周一次。
主要发现
- 7臂确认客观缓解率79.0%(95%CI 66.8-88.3),中位缓解持续时间17.6个月(95%CI 10.5-27.3)。
- 7臂中位无进展生存期14.0个月(95%CI 11.0-21.1),中位总生存期未达到。
- 8臂确认客观缓解率81.8%(95%CI 64.5-93.0),中位缓解持续时间和无进展生存期因随访短而不成熟。
- 联合方案安全性可控,与既往研究相比无新安全信号。
关键数值与推荐
- 7臂不限PD-L1表达,8臂要求PD-L1高表达(基于本地免疫组化检测)。
- 主要终点为安全性和耐受性及研究者评估的确认客观缓解率。
- 7臂中位随访35.0个月,8臂中位随访10.7个月。
临床怎么用
- 对于不可切除局部晚期或转移性三阴性乳腺癌,可考虑Dato-DXd联合度伐利尤单抗作为一线治疗选择。
- 治疗前PD-L1状态不影响该联合方案的疗效选择,但8臂数据限于PD-L1高表达人群。
- 需关注联合方案的安全性管理,尽管无新安全信号。
局限性
- 8臂随访时间较短(中位10.7个月),缓解持续时间和无进展生存期数据尚不成熟。
- 研究为开放标签、非随机平台设计,样本量有限(7臂62例,8臂33例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BEGONIA (NCT03742102) is a phase Ib/II, Simon's 2-stage, open-label, platform study evaluating the safety and efficacy of durvalumab, an anti-programmed death ligand-1 (PD-L1) antibody, combined with novel therapies, as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Arms 7 and 8 of BEGONIA assessed the combination of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, with durvalumab. PATIENTS AND METHODS: Arm 7 included patients regardless of tumor PD-L1 expression level. Arm 8 then enrolled patients with PD-L1-high tumors, as determined by local immunohistochemistry-based testing. In Arms 7 and 8, patients received Dato-DXd 6 mg/kg intravenously plus durvalumab 1120 mg intravenously every 3 weeks. Primary endpoints were safety and tolerability, and investigator-assessed confirmed objective response rate (cORR). Secondary endpoints included cORR (Part 1), duration of response (DoR), progression-free survival (PFS) per RECIST 1.1 and overall survival (OS). RESULTS: Overall, 62 and 33 patients had received Dato-DXd and durvalumab in Arms 7 and 8, respectively. At data cutoff (29 November 2024), median study follow-up was 35.0 and 10.7 months in Arms 7 and 8, respectively. In Arm 7, cORR was 79.0% [95% confidence interval (CI) 66.8-88.3], median DoR was 17.6 months (95% CI 10.5-27.3), median PFS was 14.0 months (11.0-21.1) and median OS was not reached. In Arm 8, cORR was 81.8% (95% CI 64.5-93.0). The median DoR and median PFS for Arm 8 were immature given the short median follow-up (8.3 months in censored patients). The safety profile of the combination was manageable, with no new safety signals versus prior studies. CONCLUSIONS: First-line Dato-DXd plus durvalumab demonstrated substantial and durable antitumor activity in locally advanced unresectable or metastatic TNBC, regardless of PD-L1 status.
引用
- Schmid P, Wang HC, Lynce F, et al. Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study. Ann Oncol. 2026. PMID: 42167437. doi:10.1016/j.annonc.2026.05.693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。